Afrezza news

Here are some recent news articles and updates related to Afrezza:

Recent FDA Approvals:

• In October 2020, the FDA approved Afrezza (human insulin injection) for the treatment of adult patients with type 1 diabetes and adult patients with type 2 diabetes who require insulin therapy.

Clinical Trials:

• In August 2020, MannKind Corporation, the manufacturer of Afrezza, announced the completion of a Phase 3 clinical trial evaluating the efficacy and safety of Afrezza in patients with type 2 diabetes. The trial met its primary endpoint, demonstrating non-inferiority to insulin glargine (Lantus) in terms of glycemic control.

Market Updates:

• In November 2020, MannKind Corporation announced that it had entered into a definitive agreement to be acquired by Ascendis Pharma A/S, a biopharmaceutical company focused on developing treatments for rare and endocrine diseases. The acquisition is expected to close in the first half of 2021.
• In October 2020, MannKind Corporation reported its third-quarter 2020 financial results, which included a net loss of $14.4 million and revenue of $1.4 million from the sale of Afrezza.

Product Updates:

• In September 2020, MannKind Corporation announced that it had launched a new packaging option for Afrezza, which includes a smaller, more portable inhaler and a redesigned cartridge that is easier to use.
• In August 2020, the company announced that it had expanded its patient support program for Afrezza, which now includes a dedicated customer service team and a website with resources and tools for patients and healthcare providers.

Research and Development:

• In October 2020, MannKind Corporation announced that it had initiated a Phase 2 clinical trial evaluating the use of Afrezza in patients with type 1 diabetes and cystic fibrosis-related diabetes. The trial is expected to enroll approximately 100 patients and will assess the safety and efficacy of Afrezza in this population.

I hope this information is helpful!